Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) EBIT Margin (2017 - 2026)

Organogenesis Holdings has reported EBIT Margin over the past 9 years, most recently at 28.05% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 1998.0% year-over-year to 28.05%; the TTM value through Dec 2025 reached 7.92%, up 819.0%, while the annual FY2025 figure was 7.92%, 819.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 28.05% at Organogenesis Holdings, up from 13.74% in the prior quarter.
  • Over five years, EBIT Margin peaked at 28.05% in Q4 2025 and troughed at 30.85% in Q1 2025.
  • A 5-year average of 4.43% and a median of 7.48% in 2023 define the central range for EBIT Margin.
  • Biggest five-year swings in EBIT Margin: surged 3674bps in 2021 and later plummeted -2735bps in 2025.
  • Year by year, EBIT Margin stood at 15.45% in 2021, then plummeted by -51bps to 7.55% in 2022, then tumbled by -117bps to 1.27% in 2023, then surged by 734bps to 8.07% in 2024, then skyrocketed by 248bps to 28.05% in 2025.
  • Business Quant data shows EBIT Margin for ORGO at 28.05% in Q4 2025, 13.74% in Q3 2025, and 12.45% in Q2 2025.